← Leaderboards
Jianjun Zhang
Indiana University Indianapolis
$1,819,865
Attributed
$3,639,730
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $677.8K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,639,730 · 2
By mechanism
U01$3,264,543 · 1
R21$375,187 · 1
Top collaborators
- Christian Maximillian Schmidt7 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Evan L Fogel$7,933,802
Others in their field
Top investigators on “Physicians”
- Lawrence Corey · Fred Hutchinson Cancer Center$289,810,358
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$289,810,358
- Larry Arthur$216,200,000
- Richard K. Wilson · Washington University$201,652,538
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$117,759,216
Research focus
PhysiciansPlasmaMalignant - DescriptorPathologyPancreatic CystPapillaryHigh RiskIndianaMortalityMalignant NeoplasmsMucinous NeoplasmOperative Surgical ProceduresExcisionCa-19-9 AntigenBenignClinical/RadiologicIncidenceCohortMalignant Neoplasm Of PancreasMetabolomicsBiological MarkersCystGuidelinesPredictive Marker
Grant awards (7)
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$661,420
U01 · FY2025 · CA
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$628,354
U01 · FY2024 · CA
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$648,229
U01 · FY2023 · CA
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$648,753
U01 · FY2022 · CA
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$677,787
U01 · FY2021 · CA
Identifying insulin resistance biomarkers and metabolomic signature as predictors of precursors to pancreatic cancer$171,281
R21 · FY2017 · CA · contact PI
Identifying insulin resistance biomarkers and metabolomic signature as predictors of precursors to pancreatic cancer$203,906
R21 · FY2016 · CA · contact PI